Novo Nordisk's Wegovy HD Once-Weekly Injectable Semaglutide 7.2 Mg Gets FDA Approval

Novo Nordisk has received FDA approval for its Wegovy HD once-weekly injectable semaglutide at a dosage of 7.2 mg. This approval is expected to enhance the company's position in the obesity treatment market. The stock ticker for Novo Nordisk is NVO.